According to a recent LinkedIn post from Plenful, the company is emphasizing the role of its AI platform in streamlining intake and prior authorization workflows in specialty and infusion pharmacies. The post references an interview with Plenful’s SVP of Pharmacy, Tim L’Hommedieu, featured in Specialty Pharmacy Continuum, which is described as a leading industry publication.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights claims that Plenful’s platform can reduce processing time by more than 75% while quadrupling team capacity for health systems and specialty pharmacies. It notes capabilities such as AI-powered referral intake, automated benefit verification, and prior authorization submission, positioned as enabling faster time to therapy.
For investors, the coverage in a specialized trade publication suggests growing validation and visibility of Plenful’s technology among key pharmacy stakeholders. If the reported efficiency gains are adopted at scale, this could support stronger customer acquisition and retention, underpinning revenue growth in the specialty pharmacy technology segment.
The focus on labor-intensive workflows also points to a sizeable addressable market, as pharmacies face pressure to reduce administrative burdens and improve patient access to therapies. As automation and AI become more central to pharmacy operations, Plenful’s positioning in prior authorization and referral intake could enhance its competitive standing against other healthcare workflow and AI vendors.